Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSCPA.L Regulatory News (SCPA)

  • There is currently no data for SCPA

Acquisition

2 Mar 2015 07:00

RNS Number : 1735G
Scapa Group PLC
02 March 2015
 



 

 

 

 

2 March 2015

 

Scapa Group plc

 

Acquisition of First Water Limited ("First Water" or "the Acquisition") and trading update

 

Scapa Group plc ("Scapa"), a global supplier of bonding materials and solutions, is pleased to announce that it has acquired 100% of the issued share capital of First Water Limited ("First Water") based in Ramsbury, UK. The purchase price is comprised of an initial cash consideration of £11.3m with a further cash consideration of up to £4m payable depending on performance in 2016, 2017 and 2018, for a total consideration of up to £15.3m.

 

As at 31 January 2015, unaudited gross assets acquired were £4.0m. Underlying EBITDA for the 12 months to 31 January 2015 was £0.9m on sales of £5.4m. The Acquisition is expected to be earnings enhancing in its first year.

 

First Water has built a reputation as one of the leading designer-manufacturers of advanced wound dressings and skin adhesives. Its patented adhesive polymers and dressing designs allow it to offer its OEM partners - typically multinational woundcare and consumer wellness companies - unique and compelling products for a wide range of clinical and commercial applications.

 

Background to the Acquisition

Scapa's strategy in healthcare is to become the outsourcing partner of choice to our global healthcare customers by offering turn-key solutions in our chosen market sectors of advanced woundcare, consumer wellness, medical devices and drug delivery. We believe we are well positioned to exploit the current trend in healthcare towards outsourcing while increasing our share of customers' total spend. The addition of First Water's strong patent portfolio and technological knowhow to Scapa's expertise in materials, coating and conversion capabilities significantly enhances the value proposition to our customers. First Water also brings a global customer base to which we can offer our full capabilities, leveraging our global footprint to accelerate First Water's growth.

 

First Water's highly experienced management team will remain within the enlarged Group and will strengthen Scapa's Healthcare management expertise and further facilitate the Group's growth in this sector.

 

Details of the Acquisition agreement

Scapa has acquired 100% of the issued share capital of First Water for an initial cash consideration of £11.3m (subject to adjustment following the production of a completion balance sheet to ensure normalised working capital). 

 

Three further cash payments of up to £4m in aggregate will be payable depending upon the achievement of operating profit targets over the following three financial years. The Acquisition will be funded from existing cash reserves and bank facilities.

 

Benefits of the Acquisition

The Directors believe that the Acquisition brings the following advantages to Scapa:

 

- a strengthened turn-key value proposition

- a broadened healthcare technology portfolio with proprietary and patented products

- enhanced innovation and development capabilities

- adds new global customers and potential markets

- the opportunity to leverage global sales channels providing significant cross-selling opportunities and product development potential

- improved global manufacturing infrastructure

- further acceleration of the growth of the Group's Healthcare business

- the Acquisition is expected to be earnings enhancing in the first full year of acquisition

 

Commenting on the Acquisition, Heejae Chae, Chief Executive of Scapa Group, said:

"The acquisition of First Water further enhances our strategy in healthcare to provide turn-key solutions as a strategic outsourcing partner to our global customers. First Water has a strong track record of delivering proven proprietary innovations and technologies which Scapa can now offer to our customers in consumer wellness and advanced woundcare markets in addition to expanding our offering in the medical device and drug delivery markets. Combining Scapa's strengths in material coating, converting and packaging with First Water's R&D and innovation capabilities will enable us to provide a unique one stop solution to our customers."

 

Commenting on the Acquisition, Justin Barnes and Phil Andrews, Co-owners and Directors of First Water, said:

"Becoming part of Scapa's rapidly growing global Healthcare business is a very exciting new chapter in First Water's development. From the outset, it was evident that there is great overlap and opportunity in terms of the enhanced global footprint and technology combinations that the expanded group can access. However, as important to the shareholders and employees of First Water, it was also clear that we share a common culture, a passion for what we do, and considerable care for putting our customers' priorities first. It will remain business as usual but with so much more horizon and opportunity."

 

Scapa Group current trading update

Whilst the year is not yet finished it is anticipated that the Group will have seen good growth over the same period last year, despite currency headwinds. It is anticipated that trading profits will be ahead of market expectations and we look forward to the forthcoming year with confidence. 

 

Scapa Group plc will issue a pre close update on the 9 April 2015.

 

 

 

 

Enquiries:

Scapa Group plc

Heejae Chae - Chief Executive

Paul Edwards - Finance Director

 

 

0161 301 7430

 

Numis Securities Limited

(Nominated Adviser and Joint Broker)

Mark Lander / Richard Thomas

 

 

 

020 7260 1000

 

N+1 Singer (Joint Broker)

Nick Owen

 

 

020 7496 3000

 

Weber Shandwick (Financial PR)

Nick Oborne

 

 

020 7067 0721

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQBCGDXGBGBGUB
Date   Source Headline
23rd Jul 20137:00 amRNSAGM Statement
16th Jul 20134:23 pmRNSHolding(s) in Company
5th Jul 20131:07 pmRNSHolding(s) in Company
4th Jul 201310:54 amRNSAdditional Listing
1st Jul 201312:05 pmRNSDTR 5.6.1
24th Jun 20137:00 amRNSNotice of AGM
21st Jun 20132:04 pmRNSAdditional Listing
29th May 20137:00 amRNSFinal Results
17th May 20138:30 amRNSHolding(s) in Company
7th May 20132:48 pmRNSHolding(s) in Company
7th May 201311:03 amRNSResponse to Press Speculation
26th Apr 20137:00 amRNSDisposal
16th Apr 201310:24 amRNSAdditional Listing
11th Apr 20137:00 amRNSTrading Statement
22nd Mar 201311:48 amRNSAdditional Listing
21st Mar 20137:00 amRNSResponse to Press Speculation
20th Mar 20131:26 pmRNSHolding(s) in Company
13th Mar 20137:00 amRNSStatement re Pension Deficit Funding Arrangements
28th Feb 20139:04 amRNSAdditional Listing
7th Feb 201310:28 amRNSBlocklisting Interim Review
5th Feb 201310:29 amRNSHolding(s) in Company
31st Jan 20133:19 pmRNSHolding(s) in Company
17th Jan 20139:25 amRNSAdditional Listing
16th Jan 20137:00 amRNSChange of Adviser
27th Dec 201212:13 pmRNSDirector/PDMR Shareholding
20th Dec 20127:00 amRNSDirector/PDMR Shareholding
27th Nov 20127:00 amRNSHalf Yearly Report
11th Oct 20127:00 amRNSTrading Statement
26th Sep 20124:39 pmRNSHolding(s) in Company
17th Sep 20121:54 pmRNSHolding(s) in Company
7th Aug 20129:07 amRNSBlocklisting Interim Review
24th Jul 20127:00 amRNSAGM Statement
29th Jun 20121:04 pmRNSHolding(s) in Company
29th Jun 201211:35 amRNSHolding(s) in Company
26th Jun 20129:36 amRNSNotice of AGM
30th May 201210:32 amRNSAdditional Listing
29th May 20127:00 amRNSFinal Results
17th May 20125:31 pmRNSHolding(s) in Company
17th May 20125:24 pmRNSHolding(s) in Company
2nd May 20123:39 pmRNSHolding(s) in Company
2nd May 20123:36 pmRNSHolding(s) in Company
1st May 20123:58 pmRNSAdditional Listing
30th Apr 20124:35 pmRNSHolding(s) in Company
19th Apr 201212:08 pmRNSHolding(s) in Company
13th Apr 20129:54 amRNSHolding(s) in Company
12th Apr 20127:00 amRNSPeriod end update
30th Mar 201210:55 amRNSTotal Voting Rights
29th Mar 20122:42 pmRNSHolding(s) in Company
29th Mar 20128:00 amRNSSite Visit
20th Mar 20122:10 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.